Education
About Us
Working with TipRanks
Follow Us
Innate Pharma SA (FR:IPH)
:IPH
Top Page
Innate Pharma SA
(OTC:IPH)
Select Model
Select Model
Rating:45Neutral
Price Target:
€2.00
▲(12.99% Upside)
Innate Pharma SA's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, negative profit margins, and high leverage. Technical analysis indicates a neutral trend, but valuation metrics are weak due to a negative P/E ratio and no dividend yield. The strategic focus on high-value clinical assets provides some optimism, but financial challenges remain a significant concern.
Positive Factors
Strategic Focus on High-Value Assets
Focusing on high-value clinical assets can drive long-term growth and innovation, positioning the company as a leader in oncology treatments.
Financial Stability
A strong cash position ensures the company can sustain operations and fund strategic initiatives, reducing financial risk in the near term.
Lacutamab's Potential
FDA breakthrough designation can accelerate drug approval processes, enhancing the company's competitive position and potential market impact.
Negative Factors
Declining Revenue
Substantial revenue decline indicates challenges in monetizing products and sustaining growth, affecting long-term financial health and market confidence.
High Leverage
High leverage can strain financial flexibility and increase risk, limiting the company's ability to invest in growth and innovation.
Reduction in R&D Expenses
Reduced R&D spending may hinder future innovation and product development, impacting the company's long-term competitive edge in biotechnology.
Innate Pharma SA (IPH) vs. iShares MSCI France ETF (EWQ)
Market Cap
$162.95M
Dividend YieldN/A
Average Volume (3M)174.90K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue Growth-75.86%
EPS Growth-30.54%
CountryFR
Employees181
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.25
Shares Outstanding92,183,525
10 Day Avg. Volume212,515
30 Day Avg. Volume174,895
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)13.31
Price to Sales (P/S)9.32
P/FCF Ratio-16.14
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue7.86
Enterprise Value/Gross Profit-3.23
Enterprise Value/Ebitda-2.06
Forecast
1Y Price Target
$2.00Price Target Upside13.20% Upside
Rating ConsensusHold
Number of Analyst Covering0
Innate Pharma SA Business Overview & Revenue Model
Company DescriptionInnate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
How the Company Makes MoneyInnate Pharma generates revenue primarily through collaborations and partnerships with pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on sales of products developed from their technology. The company also engages in clinical trial collaborations, licensing agreements, and may receive grant funding for specific research projects. Key revenue streams include the monetization of its drug candidates, particularly those in late-stage development or with promising clinical trial results, as well as any potential sales of products that successfully reach the market. Significant partnerships with larger pharmaceutical firms enhance its financial stability and growth prospects.
Innate Pharma SA Earnings Call Summary
Earnings Call Date:Sep 17, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Mar 19, 2026
Earnings Call Sentiment Neutral
The earnings call reflected a strategic shift towards prioritizing high-value clinical assets with promising progress in key trials. However, there were concerns over reduced R&D spending and the deprioritization of certain research areas, alongside the departure of a key scientific leader. The company's financial position remains stable, providing support for its strategic objectives.Q2-2025 Updates
Positive Updates
Strategic Focus on High-Value Clinical Assets
Innate Pharma has decided to focus its investment on three high-value clinical assets: IPH4502, lacutamab, and monalizumab, which are expected to create meaningful value for patients and shareholders.
IPH4502 Phase I Enrollment Progress
Enrollment in the first-in-human Phase I study of IPH4502 is progressing well, with completion expected by the end of Q1 2026. Preliminary safety and activity data are anticipated in the first half of 2026.
Lacutamab's Potential in CTCL
Lacutamab has received FDA breakthrough therapy designation for relapsed or refractory Sézary syndrome, with strong long-term follow-up data presented at ASCO 2025, supporting its potential for accelerated approval.
Monalizumab Phase III Trial Progress
The Phase III PACIFIC-9 trial for monalizumab, conducted by AstraZeneca, is fully recruited with primary completion expected in the first half of 2026 and data expected in the second half of 2026.
Financial Stability
Innate Pharma reported EUR 70.4 million in cash and financial assets as of June 30, 2025, providing a cash runway until the end of Q3 2026.
Negative Updates
Reduction in R&D Expenses
R&D expenses decreased by 29% compared to the previous year, reflecting the phasing of certain clinical programs, indicating a potential slowdown in broader research activities.
CSO Eric Vivier's Departure
CSO Eric Vivier is leaving his full-time position to return to academic research, although he will continue to support the company in an advisory role.
Strategic Deprioritization of NK Cell Programs
The ANKET programs and NK cell targeting have been deprioritized in the company's strategy, potentially affecting future innovation in this area.
Company Guidance
During the Innate Pharma conference call on September 17, 2025, the company provided guidance on its strategic focus and financial outlook. The company will concentrate its investments on three high-value clinical assets: IPH4502, lacutamab, and monalizumab, which have the potential to transform cancer care. Innate Pharma is undertaking a strategic refocus and organizational streamlining with a cash runway extending to the end of the third quarter of 2026. Financial results for the first half of 2025 included total revenue of EUR 4.9 million and operating expenses of EUR 30.3 million. The company reported EUR 70.4 million in cash, cash equivalents, and financial assets as of June 30, 2025. Innate Pharma aims to complete enrollment in the IPH4502 Phase I trial by Q1 2026, with preliminary data expected in the first half of 2026. Meanwhile, they plan to advance lacutamab to Phase III, targeting a potential accelerated approval in 2027, and anticipate Phase III data for monalizumab in H2 2026.Innate Pharma SA Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.64M | 12.62M | 51.90M | 49.64M | 12.11M | 69.77M |
| Gross Profit | -30.79M | -31.86M | 5.62M | 6.01M | -34.89M | 20.07M |
| EBITDA | -48.11M | -50.99M | -1.84M | -61.30M | -43.23M | 13.30M |
| Net Income | -46.05M | -49.47M | -7.57M | -58.10M | -52.81M | -63.98M |
Balance Sheet | ||||||
| Total Assets | 92.94M | 111.06M | 184.19M | 207.86M | 267.50M | 307.42M |
| Cash, Cash Equivalents and Short-Term Investments | 60.03M | 80.77M | 92.46M | 101.48M | 119.84M | 151.64M |
| Total Debt | 27.03M | 31.00M | 39.89M | 42.25M | 44.25M | 19.09M |
| Total Liabilities | 87.79M | 102.22M | 132.29M | 153.71M | 160.06M | 151.45M |
| Stockholders Equity | 5.14M | 8.83M | 51.90M | 54.15M | 107.44M | 155.97M |
Cash Flow | ||||||
| Free Cash Flow | -41.26M | -7.29M | -34.91M | -20.28M | -59.79M | -63.09M |
| Operating Cash Flow | -41.10M | -6.90M | -32.56M | -19.15M | -58.46M | -51.81M |
| Investing Cash Flow | 15.24M | 9.20M | 20.63M | 1.88M | -917.00K | -13.37M |
| Financing Cash Flow | 8.79M | -6.01M | -1.97M | -1.83M | 26.82M | -1.14M |
Innate Pharma SA Technical Analysis
Positive
1.77
Price Trends
1.81
Positive
1.76
Positive
1.83
Negative
Market Momentum
-0.02
Negative
59.20
Neutral
79.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:IPH, the sentiment is Positive. The current price of 1.77 is above the 20-day moving average (MA) of 1.70, below the 50-day MA of 1.81, and below the 200-day MA of 1.83, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 59.20 is Neutral, neither overbought nor oversold. The STOCH value of 79.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:IPH.
Innate Pharma SA Peers Comparison
UnderperformOutperform
Sector (51)
FR:IPH
Innate Pharma SA
1.77
-0.19
-9.52%
GNFTF
Genfit
3.72
-1.83
-32.97%
GB:0QAJ
DBV Technologies
2.34
1.65
239.13%
GB:0QAV
Nanobiotix
18.64
13.94
296.60%
DE:6OP
OSE Immunotherapeutics SA
6.98
-1.83
-20.77%
DE:RFM
Sensorion SAS
0.33
-0.39
-54.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.